152802-65-8

Usage

Uses

Used in Soap and Detergent Industry:
ETHYL 2-AMINO-2-ETHYLHEXANOATE is used as a surfactant for its ability to reduce the surface tension of water, which makes it more effective at removing dirt and debris.
Used in Cosmetics Industry:
ETHYL 2-AMINO-2-ETHYLHEXANOATE is used as a skin-conditioning and moisturizing ingredient, enhancing the texture and feel of cosmetic products, and providing a more pleasurable consumer experience.
Used in Hair Care Products:
ETHYL 2-AMINO-2-ETHYLHEXANOATE is used as a hair conditioning agent, contributing to the improved manageability and appearance of hair.

InChI:InChI=1/C10H21NO2/c1-4-7-8-10(11,5-2)9(12)13-6-3/h4-8,11H2,1-3H3

Upstream product

• 152802-64-7 ethyl 2-(benzylideneamino)-2-ethylhexanoate 
• 55410-21-4 ethyl 2-aminobutyrate hydrochloride 
• 78843-65-9 Ethyl (E)-2-(benzylideneamino) butanoate 
• 58577-05-2 2-amino-2-ethylhexanonitrile 
• 106-35-4 heptan-3-one 
• 64-17-5 ethanol 
• 6300-78-3 2-Amino-2-ethyl-hexanoic acid 

Downstream Products

• 114781-15-6 (S)-2-amino-2-ethylhexanoic acid 
• 151851-75-1 (+/-)-2-amino-2-ethylhexan-1-ol 
• 151851-75-1 (R)-2-amino-2-ethylhexan-1-ol 
• 114781-14-5 (R)-2-amino-2-ethylhexanoic acid 
• 164262-42-4 ethyl (S)-2-amino-2-ethylhexanoate 

Relevant academic research and scientific papers

BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS

The invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS

The invention relates to 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention a

BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS

The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

Hypolipidemic 1,4-benzothiazepine derivative

The invention is concerned with a novel hypolipidemic compound, which is of (3R,5R)-3-Butyl-3-ethyl-2,3,4,5-tetrahydro-7-methoxy-5-phenyl-1,4-benzothiazepin-8-ol 1,1-dioxide; or a salt, solvate, or physiologically functional derivative thereof, with processes for its preparation, pharmaceutical compositions containing it and with its use in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions, such as athersclerosis.

The first fully planar C5-conformation of homooligopeptides prepared from a chiral α-ethylated α,α-disubstituted amino acid: (S)-butylethylglycine (=(2S)-2-amino-2-ethylhexanoic acid)

An optically active α-ethylated α,α-disubstituted amino acid, (S)-butylethylglycine (=(2S)-2-amino-2-ethylhexanoic acid; (S)-Beg; (S)-2), was prepared starting from butyl ethyl ketone (1) by the Strecker method and enzymatic kinetic resolution of the racemic amino acid. Homooligopeptides containing (S)-Beg (up to hexapeptide) were synthesized by conventional solution methods. An ethyl ester was used for the protection at the C-terminus, and a trifluoroacetyl group was used for the N-terminus of the peptides. The structures of tri-and tetrapeptides 5 and 6 in the solid state were solved by X-ray crystallographic analysis, and were shown to have a bent planar C5-conformation (tripeptide) and a fully planar C5-conformation (tetrapeptide) (see Figs. 1 and 2, resp.). The IR and 1H-NMR spectra of hexapeptide 8 revealed that the dominant conformation in CDCl3 solution was also a fully planar C5-conformation. These results show for the first time that the preferred conformation of homopeptides containing a chiral α-ethylated α,α-disubstituted amino acid is a planar C5-conformation.

Chemo-Enzymic Synthesis of Optically Active α,α-Disubstituted α-Amino Acids

A series of α,α-disubstituted α-amino esters was chemically synthesized and then resolved through enantioselective hydrolysis catalysed by a new enzyme isolated from crude Humicola langinosa lipase.This enzyme only accepts free amino esters as substrates with neither lipase activity toward olive oil nor esterase activity toward o-nitrophenyl butyrate.It is unique in that it successfully catalyses the resolution of amino esters with two large α-alkyl groups including aliphatic, aromatic and cyclic amino esters.Examples of resolutions where the alkyl groups differ in size by as little as a single carbon atom have been demonstrated.For determination of absolute configuration, some of the optically active α,α-disubstituted amino acids were also prepared through Schoellkopf's asymmetric synthesis and the structures were verified by X-ray crystallography.A model depicting the substrate binding site of the enzyme is proposed.